CP-346086

Cat. No.:	HY-113955
CAS No.:	186390-48-7
Molecular Formula:	$C_{26}H_{22}F_3N_5O$
Molecular Weight:	477.48
Target:	Microsomal Triglyceride Transfer Protein (MTP)
Pathway:	Metabolic Enzyme/Protease
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (209.43 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.0943 mL	10.4716 mL	20.9433 mL
	5 mM	0.4189 mL	2.0943 mL	4.1887 mL
	10 mM	0.2094 mL	1.0472 mL	2.0943 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

CP-346086 is a potent and orally active microsomal triglyceride transfer protein (MTP) inhibitor, with an IC_{50} of 2.0 nM for human and rodent MTP. CP-346086 can lower plasma cholesterol and triglycerides in vivo[1].

IC_{50} & Target

IC50: 2.0 nM (MTP)[1]

In Vitro

CP-346086 (0.1-1000 nM) dose-dependently inhibits human MTP-mediated triglyceride transfer between vesicles with an IC_{50} of 2.0 nM[1].

CP-346086 (24 h) inhibits apolipoprotein B (apoB) and triglyceride secretion (IC_{50}=2.6 nM) from Hep-G2 cells without affecting apoA-I secretion or lipid synthesis[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

CP-346086 (1-100 mg/kg; oral gavage once daily for 2 weeks) reduces plasma total, VLDL, and LDL cholesterol and triglycerides in mice[1].

CP-346086 (25 mg/kg; a single p.o.) results in an almost complete inhibition of Tyloxapol-induced triglyceride accumulation in fasted rats[1].

CP-346086 (0.1-10 mg/kg; a single p.o.) reduces acute plasma triglyceride in mice[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	B6CBAF1J mice[1]
Dosage:	1, 2, 10, 20, 100 mg/kg
Administration:	Oral gavage once daily for 2 weeks
Result:	Lowered total, VLDL, and LDL cholesterol and triglycerides dose dependently with 23%, 33%, 75%, and 62% reductions at 10 mg/kg/day.

REFERENCES

[1]. Chandler CE, et, al. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res. 2003 Oct;44(10):1887-901.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA